RIGEL PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Rigel Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2020 to Q3 2024.
  • Rigel Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $12.4M.
  • Rigel Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $3.88M.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$25.1M, a 57.2% increase from 2022.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$58.6M, a 227% decline from 2021.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$17.9M, a 39.8% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.88M $12.4M +$18.1M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$14.2M -$1.03M +$5.57M +84.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$19.8M -$8.25M +$5.29M +39.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$25.1M $737K -$664K -47.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$24.4M -$5.69M +$13.3M +70.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$37.8M -$6.6M +$6.89M +51.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$44.7M -$13.5M +$13.9M +50.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$58.6M $1.4M +$24M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$82.6M -$19M +$1.92M +9.14% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$84.5M -$13.5M +$329K +2.38% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 -$84.9M -$27.4M -$66.9M -169% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 -$17.9M -$22.6M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 -$21M -$6.78M -47.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$13.8M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $39.5M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q3 2020 -$14.2M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.